Efficacy and safety of oral treatment twice daily with H 376/95 (ximelagatran), preceded by subcutaneous injections with melagatran, compared with dalteparin subcutaneous once daily, as prophylaxis against thromboembolic complications after total hip or knee replacement (METHRO II)
Study identifier:SH-TPO-0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Efficacy and safety of oral treatment twice daily with H 376/95 (ximelagatran), preceded by subcutaneous injections with melagatran, compared with dalteparin subcutaneous once daily, as prophylaxis against thromboembolic complications after total hip or knee replacement (METHRO II)
Medical condition
venous thromboembolism
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Sept 1998
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
